Researchers at the University of Pittsburgh have identified a trigger of high-grade serous ovarian cancer: a subset of progenitor cells that reside in fallopian tube supportive tissue, or stroma.
FDA has approved Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy. Avmapki Fakzynja Co-Pack is the first and only FDA-approved medicine for this disease.
